The FDA has authorized, with special controls, the first direct-to-consumer (DTC) test to report specific BRCA1/BRCA2 breast cancer gene mutations. The authorization means 23andMe, the personal genetics company, can now provide its customers with information on three variants found in the BRCA1 and BRCA2 genes associated with a higher risk of breast, ovarian and prostate cancer. No prescription is required.